SG151072A1 - Stabilization of macrolides - Google Patents

Stabilization of macrolides

Info

Publication number
SG151072A1
SG151072A1 SG200302502-0A SG2003025020A SG151072A1 SG 151072 A1 SG151072 A1 SG 151072A1 SG 2003025020 A SG2003025020 A SG 2003025020A SG 151072 A1 SG151072 A1 SG 151072A1
Authority
SG
Singapore
Prior art keywords
stabilization
macrolides
poly
relates
crystalline form
Prior art date
Application number
SG200302502-0A
Other languages
English (en)
Inventor
Francois Navarro
Samuel Petit
Guy Stone
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG151072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG151072A1 publication Critical patent/SG151072A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SG200302502-0A 1998-12-07 1999-12-06 Stabilization of macrolides SG151072A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
SG151072A1 true SG151072A1 (en) 2009-06-29

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200302502-0A SG151072A1 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Country Status (38)

Country Link
US (5) US6605613B2 (it)
EP (4) EP2279751A3 (it)
JP (3) JP3805625B2 (it)
KR (2) KR20060096477A (it)
CN (2) CN1261163C (it)
AR (3) AR026102A1 (it)
AT (1) ATE365051T1 (it)
AU (1) AU759219B2 (it)
BE (1) BE1012869A3 (it)
BR (1) BR9915986A (it)
CA (3) CA2732620C (it)
CO (1) CO4980847A1 (it)
CY (1) CY1106870T1 (it)
CZ (2) CZ302210B6 (it)
DE (1) DE69936352T3 (it)
DK (1) DK1137439T4 (it)
ES (1) ES2288033T5 (it)
FR (1) FR2786771B1 (it)
GB (2) GB9826882D0 (it)
HK (1) HK1038889B (it)
HU (2) HU228939B1 (it)
ID (1) ID29250A (it)
IL (1) IL143092A0 (it)
IT (1) IT1319701B1 (it)
MY (2) MY120594A (it)
NO (2) NO332698B1 (it)
NZ (2) NZ511936A (it)
PE (1) PE20001333A1 (it)
PL (2) PL196627B1 (it)
PT (1) PT1137439E (it)
RU (1) RU2243769C2 (it)
SG (1) SG151072A1 (it)
SI (1) SI1137439T2 (it)
SK (2) SK286688B6 (it)
TR (2) TR200101416T2 (it)
TW (2) TWI248938B (it)
WO (1) WO2000033878A2 (it)
ZA (1) ZA200104360B (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
KR20040086369A (ko) 2002-02-13 2004-10-08 비오갈 기오기스제르갸르 알티. 바이오매터로부터 마크롤라이드를 추출하는 방법
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
TR200500302T3 (tr) 2003-03-31 2005-04-21 Biogal Gyogyszergyar Rt. Makrolidlerin kristalizasyonu ve saflaştırılması.
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
KR20060052874A (ko) 2003-07-24 2006-05-19 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 정제 방법
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CA2548596A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd. Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
JP2008514706A (ja) * 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
KR20080077147A (ko) * 2005-12-07 2008-08-21 와이어쓰 결정성 라파마이신의 제조 방법 및 시차 주사 열량계를사용하는 라파마이신 화합물의 결정화도의 측정 방법
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
WO2007075621A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
AU2007212271B2 (en) * 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2011156025A1 (en) * 2010-06-07 2011-12-15 Telik, Inc. Crystalline Ezatiostat Hydrochloride Ansolvate
CN103140494A (zh) * 2010-08-04 2013-06-05 美利奴生命科学有限公司 制备具有抗增殖特性的新的42-o-（杂烷氧基烷基）雷帕霉素化合物的方法
CA2818225C (en) 2010-11-19 2016-10-25 Biocon Limited Processes for preparation of everolimus and intermediates thereof
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (it) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
WO2017038612A1 (ja) * 2015-08-28 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
JP7020914B2 (ja) * 2015-09-18 2022-02-16 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
US20190290631A1 (en) 2016-05-27 2019-09-26 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
WO2021194772A1 (en) * 2020-03-27 2021-09-30 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) * 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ATE321053T1 (de) 1992-10-13 2006-04-15 Wyeth Corp Carbamate von rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
WO1996041807A1 (en) * 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
EP1208847B8 (en) * 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
EP0975330A1 (en) 1997-02-04 2000-02-02 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
HU230174B1 (hu) 2015-09-28
TR200201428T2 (tr) 2002-12-23
TW200540179A (en) 2005-12-16
CO4980847A1 (es) 2000-11-27
JP2005200429A (ja) 2005-07-28
GB9826882D0 (en) 1999-01-27
DE69936352D1 (de) 2007-08-02
DK1137439T3 (da) 2007-09-10
GB9904934D0 (en) 1999-04-28
KR20010101128A (ko) 2001-11-14
NO20012424L (no) 2001-05-16
SI1137439T1 (sl) 2008-06-30
TWI270550B (en) 2007-01-11
JP5165199B2 (ja) 2013-03-21
AU759219B2 (en) 2003-04-10
FR2786771A1 (fr) 2000-06-09
WO2000033878A3 (en) 2000-11-02
CZ20012001A3 (cs) 2001-09-12
NZ511936A (en) 2003-10-31
MY120594A (en) 2005-11-30
CN1876657B (zh) 2013-01-09
JP3805625B2 (ja) 2006-08-02
AR026102A1 (es) 2003-01-29
ITMI992520A1 (it) 2001-06-02
ES2288033T3 (es) 2007-12-16
CZ302210B6 (cs) 2010-12-22
PT1137439E (pt) 2007-09-25
NZ527781A (en) 2004-11-26
ES2288033T5 (es) 2012-04-10
HUP0104489A2 (hu) 2002-03-28
JP5043308B2 (ja) 2012-10-10
TR200101416T2 (tr) 2002-01-21
CA2732620C (en) 2013-08-06
CA2351580C (en) 2012-03-20
CA2732620A1 (en) 2000-06-15
EP2279751A2 (en) 2011-02-02
DE69936352T2 (de) 2008-02-14
HK1038889A1 (en) 2002-04-04
JP2006111637A (ja) 2006-04-27
EP2269651A3 (en) 2011-03-09
CN1261163C (zh) 2006-06-28
NO334612B1 (no) 2014-04-22
RU2243769C2 (ru) 2005-01-10
PL348333A1 (en) 2002-05-20
NO20012424D0 (no) 2001-05-16
SK286688B6 (sk) 2009-03-05
SK287325B6 (sk) 2010-07-07
WO2000033878A2 (en) 2000-06-15
CZ303006B6 (cs) 2012-02-22
CY1106870T1 (el) 2012-09-26
EP1137439B2 (en) 2011-11-23
EP2279751A3 (en) 2011-02-16
AU1657300A (en) 2000-06-26
PE20001333A1 (es) 2000-12-12
DK1137439T4 (da) 2012-03-19
US20090270441A1 (en) 2009-10-29
MY127579A (en) 2006-12-29
US20050107418A1 (en) 2005-05-19
US7572804B2 (en) 2009-08-11
US20080161334A1 (en) 2008-07-03
IL143092A0 (en) 2002-04-21
HUP0104489A3 (en) 2004-05-28
JP2002531527A (ja) 2002-09-24
AR048073A2 (es) 2006-03-29
HU228939B1 (en) 2013-07-29
ZA200104360B (en) 2002-01-16
ITMI992520A0 (it) 1999-12-02
PL196627B1 (pl) 2008-01-31
DE69936352T3 (de) 2012-05-03
EP2269651A2 (en) 2011-01-05
EP1137439A2 (en) 2001-10-04
IT1319701B1 (it) 2003-10-27
FR2786771B1 (fr) 2002-12-27
US6605613B2 (en) 2003-08-12
CN1876657A (zh) 2006-12-13
CN1374872A (zh) 2002-10-16
SI1137439T2 (sl) 2012-05-31
US7297703B2 (en) 2007-11-20
KR100695834B1 (ko) 2007-03-19
BE1012869A3 (fr) 2001-04-03
ATE365051T1 (de) 2007-07-15
ID29250A (id) 2001-08-16
US7741338B2 (en) 2010-06-22
BR9915986A (pt) 2001-09-04
PL208854B1 (pl) 2011-06-30
US6852729B2 (en) 2005-02-08
AR054444A2 (es) 2007-06-27
EP1743657A2 (en) 2007-01-17
US20020032213A1 (en) 2002-03-14
CA2651609A1 (en) 2000-06-15
CA2351580A1 (en) 2000-06-15
SK7662001A3 (en) 2001-12-03
TWI248938B (en) 2006-02-11
HK1038889B (zh) 2008-01-25
EP1137439B1 (en) 2007-06-20
NO332698B1 (no) 2012-12-10
NO20121113L (no) 2001-05-16
US20030191148A1 (en) 2003-10-09
EP1743657A3 (en) 2007-03-28
KR20060096477A (ko) 2006-09-11

Similar Documents

Publication Publication Date Title
MY120594A (en) Stabilization of macrolides
AU759511C (en) Breast stabilization devices and methods
IL137024A0 (en) Novel macrolides
GB9907802D0 (en) Doping
IL136721A0 (en) Novel erythromycin derivatives
GB2338378B (en) Signal-related displays
IL142628A0 (en) Novel macrolide antibiotics
HRP980189B1 (en) Novel 15-membered lactams ketolides
AU4139799A (en) Improvements in macrolide production
SG83724A1 (en) Novel polyene macrolide compounds and uses
KR20010006560A (ko) 터널시공장치
HUP0103853A2 (hu) Táplálékmegvonásra alkalmazható készítmények és eljárások
SG74707A1 (en) Cyclic bis-phosphites and compositions
GB9805464D0 (en) Construction of ioniser
AU3421799A (en) Microcalorimeter
AU4358199A (en) First aid pillow
AU2003200370A1 (en) Stabilization of macrolides
AU1480801A (en) Compositions and methods for the diminution or elimination of various cancers
GB9817948D0 (en) Comforter
GB9813881D0 (en) Plough point arrangement
IL140003A0 (en) Erythromycin compositions
ZA99851B (en) Crystalline TNF-α-converting enzyme and uses thereof.
GB9820406D0 (en) Growth factors
AU2002302032A1 (en) Novel Macrolides
AUPP128398A0 (en) The growing solutions channel